Arthneeti
All Q4 FY26 results →
W

Wockhardt Ltd

Q4 FY26

Wockhardt Q4 FY26 earnings call: Revenue & Margins

Q4 FY26 earnings call: what management said on revenue, margins and capex.

Price₹1,886
Market cap₹32.6K Cr
P/E114.8
Updated23 Aug 2026
Read4 min read

What the Q4 FY26 call signalled

2 of 3 strong

RevenueGood growth
MarginMargins steady
CapexCapex planned

The short version

Future growth expectations for Wockhardt Limited as per the document include: - Slow initial increase in revenue from new molecules like Zaynich, with a hockey-stick growth trajectory expected after 12-18 months. Wockhardt expects a significant growth trajectory in revenue and profitability over the next 12-18 months, especially from the novel antibiotic business like Zaynich, with a "hockey stick" growth pattern post initial commercialization phase.

From Wockhardt Ltd's Q4 FY26 earnings-call transcript · updated 23 Aug 2026.

Revenue & Sales Performance

Good growth
Future growth expectations for Wockhardt Limited as per the document include: - Slow initial increase in revenue from new molecules like Zaynich, with a hockey-stick growth trajectory expected after 12-18 months. - Significant market share goal of about 20-25% of resistant cases long-term. - Biosimilar business to double within 24 to 36 months driven by capacity expansion and pipeline product launches. - Capex of INR 200-300 crores planned over next three years, mainly in biologicals capacity. - Initial 12-18 months of slight loss or neutral profitability expected during market organization establishment for Zaynich, followed by strong profitability growth. - Overall company growth inherent due to multiple molecules without needing acquisitions. - India biosimilar market opportunity estimated at $6-7 billion.

2 more points from Wockhardt Ltd's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Wockhardt Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

Capex planned
  • Planned capex over next three years: INR 200 to 300 crores, mainly for expanding biologicals capacity (Page 14).
  • Investment in increasing biosimilar capacity, aiming to double capacity within 12 to 15 months (Page 26).
  • Continued R&D spends at a consistent percentage of sales to support product pipeline development (Page 14).
  • Focus on building a new business model and organizational capabilities for commercialization of innovative drugs like Zaynich, involving upfront revenue costs rather than capex (Page 14).

2 more points from Wockhardt Ltd's call on capex

Create a free account to keep reading this call

Fundraising & Capital Structure

See what Wockhardt Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

See what Wockhardt Ltd said on order book & pipeline — free account, 30 seconds.

Wockhardt Ltd — Quarterly revenue & net profit

Revenue Net profit Net loss
Dec 2024Q3 FY25
Mar 2025Q4 FY25
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26

Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹965 Cr, net profit ₹164 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Continue your research

What Wockhardt Ltd's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

  • Balaxi Pharmaceuticals Ltd (Q4 FY26)

    Q4 FY26 consolidated revenue: ₹70.71 crore, down 7.3% YoY from ₹76.27 crore in Q4 FY25 (Page 22). Key investor presentation takeaways from Balaxi Pharma's Q4 FY

  • Accretion Pharmaceuticals Ltd (Q4 FY26)

    45.89 crore, up 18.24% YoY (Page 28). Key investor presentation takeaways from Accretion Pharmaceuticals Ltd's Q4 FY26 investor presentation — and how it ranks

  • Gujarat Themis Biosyn Ltd (Q4 FY26)

    . Key investor presentation takeaways from Gujarat Themis Biosyn Ltd's Q4 FY26 investor presentation — and how it ranks against sector peers.

  • Aptus Pharma Ltd (Q4 FY26)

    The investor presentation reports quarterly revenue of ₹40.36 crore for Q4 FY2026. Key concall takeaways from Aptus Pharma Ltd's Q4 FY26 earnings call — and…

Compare:vs Sun Pharma.Inds.vs Divi's Lab.vs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Wockhardt Ltd and 15K+ more earnings calls,
for less than your morning chai

a day

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Wockhardt Ltd Q4 FY26 results?

Future growth expectations for Wockhardt Limited as per the document include: - Slow initial increase in revenue from new molecules like Zaynich, with a hockey-stick growth trajectory expected after 12-18 months. Wockhardt expects a significant growth trajectory in revenue and profitability over the next 12-18 months, especially from the novel antibiotic business like Zaynich, with a "hockey stick" growth pattern post initial commercialization phase.

What is Wockhardt Ltd share price analysis?

Wockhardt Ltd currently shows a moderate growth signal based on ranking data. The stock trades at a P/E of 114.8 with a market cap of ₹32,598 Cr. Investors should review the full earnings analysis for detailed insights.

Is Wockhardt Ltd planning capital expenditure?

Planned capex over next three years: INR 200 to 300 crores, mainly for expanding biologicals capacity (Page 14).

Keep Wockhardt Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.